H
istorical records indicate that the origins of phototherapy date back to ancient Egypt when it was discovered that ingestion of the Ammi majus plant, followed by sunbathing on the banks of the Nile River, would restore melanin production in persons suffering from vitiligo. 1 Thirty years ago a new treatment modality, developed on the principles of phototherapy, was shown to benefit patients with steroid resistant cutaneous T-cell lymphoma (CTCL). 2 The US Food and Drug Administration (FDA) approved the first closed-system extracorporeal photopheresis (ECP) device, Therakos XTS, in 1988. The latest, third-generation device, developed by the same manufacturer, Therakos Cellex, was approved for use in the United States, Canada, and Europe by 2009 (Therakos division of Mallinckrodt Pharmaceuticals). Since the introduction of ECP the number of entities treated by this therapy remains relatively small. CTCL is still the only FDA-approved indication for ECP in the United States, but given the overwhelming evidence of benefit in chronic graft-versus-host disease (GVHD) and more modest benefits shown for heart allograft rejection, the Centers for Medicare and Medicaid Services (CMS) released a national coverage decision memo (CAG-00324R) allowing ECP reimbursement for these additional entities. In 2012, CMS expanded coverage to include treatment of bronchiolitis obliterans syndrome after lung allograft rejection provided that the therapy was administered through a CMS-approved research program (CAG-00324R2). Although ECP is used for the treatment of numerous autoimmune diseases, these entities are rarely treated with ECP in the United States because of little to no reimbursement by insurance providers. 3 The American Society for Apheresis (ASFA) and the European Dermatology Forum have published guidelines for ECP use in the United States and around the world. The American Society for Apheresis evidence-based guidelines are published approximately every 3 years and provide the user with a category specifying the use of ECP for a given indication and other practical information such as timing and duration of treatment and technical considerations. 4 The European Dermatology Forum guidelines are based on published literature, expert opinion, and consensus agreement in addition to recommendations for treatment schedules and response assessment. 
TECHNICAL ASPECTS AND MECHANISMS OF ACTION
The ECP procedure consists of three sequential phases: collection of buffy coat, photoactivation with ultraviolet A (UV-A) light, and reinfusion of treated cells. The procedure can be performed using a "closed" system that incorporates all three phases into one device or with an "open" system that consists of separate instrumentation for the leukapheresis and photoactivation phases. 5, 6 During the collection phase whole blood is centrifuged and separated into its components. White blood cells (WBCs) are collected into a treatment reservoir while plasma and red blood cells (RBCs) are returned to the patient. After a sufficient amount of buffy coat is collected a photoreactive chemical isolated from the A. majus plant, 8-methoxypsoralen (8-MOP), is added to the treatment bag. The 8-MOP formulation is FDA approved and commercially known as UVADEX. 8-MOP intercalates between DNA strands and forms weak bonds with cellular proteins. 5, 6 The photoactivation phase occurs when the buffy coat/8-MOP suspension is irradiated. UV-A light activates the 8-MOP causing DNA crosslinking and cellular protein modifications. This particular form of cellular damage causes most of the treated WBC undergo apoptosis. However, recent studies suggest that cellular differentiation may also occur during this phase. 7 After photoactivation the treated buffy coat is returned to the patient. Although ECP has been in use for 30 years, the mechanism of action remains elusive. How does ECP mediate anticancer immunotherapy in the setting of CTCL but tolerance in the setting of GVHD when the delivery of the therapy is exactly the same for both conditions? Recent studies published by Edelson and colleagues 8, 9 suggest that differential monocyte maturation into mature and immature dendritic cells during the photoactivation phase explains the polarized responses that allow for both immunity and tolerance, respectively. Another hypothesis postulates that ECP-treated, active alloreactive T cells rapidly undergo apoptosis and are preferentially phagocytized by dendritic cells triggering maturation. The mature dendritic cells display peptides from pathogenic alloreactive T cells resulting in the induction of anticlonotypic responses against alloreactive T-cell clones that are mediating disease. The details supporting these hypotheses are beyond the scope of this paper and are reviewed elsewhere.
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CLOSED VERSUS OPEN ECP SYSTEMS
Currently there are two closed system Therakos instruments available, the UVAR-XTS and Cellex. Both use the Latham bowl for cell separation and buffy coat collection and the photoactivation chamber is integrated into the instruments to allow all three ECP phases to occur on one device. The Therakos UVAR-XTS is a discontinuous-flow instrument that can only be used in "single-needle mode" meaning that the same vascular access site is used for collection of whole blood and return of plasma, RBCs, and treated buffy coat. The Therakos Cellex instrument can operate in both discontinuous and continuous modes. The continuous, "double-needle mode" requires separate collection and return vascular sites. If the procedure starts in double-needle mode and one of the access sites is lost the mode can be converted to single needle for the completion of the therapy. 11 The Cellex has shorter treatment times due to the option for continuous mode with dual access, faster processing of blood, and photoactivation. Additionally, the ability to adjust the centrifuge bowl optic sensor at the plasma/RBC interface may aid the operator when the patient has severe lipemic or icteric plasma. The extracorporeal volume (ECV) of the UVAR-XTS is variable and may exceed 600 mL depending on the selected size of the Latham bowl (125 or 225 mL) and cycle of the discontinuous procedure. The ECV of the Cellex is lower, as low as 216 mL in dual-needle mode and 266 mL in singleneedle mode. 11 However, these volumes may increase depending on the return bag threshold volume, which may be adjusted from 100 to 500 mL. The low ECV of the Cellex allows for smaller-body-weight patients to be safely treated and reduces the likelihood of hypotensive episodes and allows patients with lower body weights. The recommended max inlet rate for both instruments is 50 mL/min but can be considerably slower depending on patient tolerance and vascular access cooperation. Open systems use separate devices for leukapheresis and UV-A irradiation. The devices are validated and approved for their separate uses but not together. The open system requires that the leukapheresis product be disconnected from the patient for the photoactivation phase, which increases the potential for contamination or reinfusion of the treated product into the wrong patient. 5 Because vascular access options for leukapheresis procedures are detailed in a separate review of this supplemental edition of TRANSFUSION, only vascular access options for closed-system ECP devices are described in this article.
VASCULAR ACCESS AND ECP
The duration of treatment for patients undergoing ECP therapy is months to years. Many patients will start with intensive therapy, for example, two consecutive ECP treatments at weekly or 2-week intervals. Some protocols adhere to a prescribed treatment plan for the number and timing of ECP whereas other protocols modify treatment intervals based on patient response. Regardless, patients who commit to ECP will need long-term vascular access that will not collapse under the negative pressures associated with the collection phase of ECP. The results of a recent international survey of ECP practice found that venous access issues were the number one reason given as a barrier to patients receiving ECP therapy at their center. 12 Several considerations must be evaluated before selecting a vascular access route for the ECP patient. The ideal route allows for safe, successful completion of ECP; negligible risks of infection or other complications; and minimal interference with the patient's quality of life.
PERIPHERAL VEINS
Peripheral venous access for ECP requires at least one vein of adequate size and rigidity to accommodate the negative and positive pressures associated with the collection and return of blood during the procedure. Typically antecubital veins are cannulated using 16-to 18-gauge steel dialysis needles. If a patient has adequate peripheral veins in both arms then the double-needle mode can be employed when using the Cellex device. The return site is generally cannulated with a peripheral intravenous (IV) catheter, for example, 18-gauge polyurethane catheters, since the vein will only be exposed to positive pressure during the return of blood to the patient.
Peripheral vein cannulation carries a very low risk of serious complications, especially when compared to the implanted vascular access devices (IVADs). 13 Utilization of peripheral veins for apheresis procedures varies considerably between institutions in the United States and internationally. 14 Recent reports from two apheresis programs in the United States demonstrate this variability. One apheresis center (approx. 800 procedures/year) reported that peripheral cannulation was used for access in less than 5% of apheresis procedures whereas a larger center (approx. 3500 procedures/year) that routinely uses ultrasound-guided venipuncture reported peripheral vascular access routes for 64% of apheresis procedures. 15, 16 The authors speculate that the discrepancies are due, in part, to the apheresis providers' degree of comfort, use of ultrasound, experience, and technical skills related to peripheral vein cannulation for apheresis therapies. When peripheral vein cannulation is not an option for ECP, IVAD must be considered.
NONTUNNELED CENTRAL VENOUS CATHETERS
These temporary central venous catheters (CVCs) may be appropriate for short-term apheresis therapies (1-2 weeks) but they are not recommended for ECP due to the expected duration of therapy.
TUNNELED CVCs
Tunneled CVCs (TCVCs) may be used for ECP and other chronic apheresis therapies expected to last from weeks to years. Most TCVCs are dual-lumen catheters (10-13.5 Fr) made from polyurethane or silicone, materials that are flexible enough to minimize vascular injury yet have sufficient rigidity to maintain patency during high-flow rates. 17 The purpose of tunneling through the subcutaneous tissue before central vein cannulation is to reduce the risks of sepsis by separating the skin insertion site from the vascular access site. 17 Most TCVC models are designed with a polyester cuff that is located within the subcutaneous tunnel near the skin insertion site. As the tunneled tract heals around the catheter, the cuff forms a mechanical seal between the skin and venous insertion sites further reducing the risk of infection. Fluoroscopy is used to assist placement of TCVC. A standard approach is to tunnel through the subcutaneous tissue on the right side of the chest to access the right internal jugular vein. 17 This allows for a relatively straight course to direct the catheter tip to the superior vena cava (SVC)/right atrial junction. The left-sided approach is more challenging due to the angle the catheter must traverse between the left internal jugular vein and the innominate vein into the SVC. Tunneled access into the subclavian vein should only be used when there are no other options for vascular access. This route has the highest risks for complications including pneumothorax and central vein stenosis. 18, 19 Appropriate maintenance and care of the TCVC is essential to prevent catheter-related bloodstream infections (CRBSIs). These infections significantly increase hospital stays and medical costs; however, the direct contribution of CRBSI to mortality is still under debate. 20 A meta-analysis of 200 published studies of prospectively evaluated CRBSI show that cuffed TCVC rate of infection is 1.6 per 1000 intravascular device (IVD) days. 13 For comparison, the rate of CRBSI with peripheral IV catheters is only 0.5 per 1000 IVD days. The Centers for Disease Control and Prevention (CDC) recently published guidelines for the prevention of CRBSI. 20 The TCVC exit site should be covered with sterile gauze or a sterile, transparent semipermeable membrane until the tunneled site heals. Dressings should be replaced no more than once per week unless they are soiled. Chlorohexidine-impregnated sponges may be applied at the exit site to reduce infections. Dressing well-healed exit sites for TCVC is controversial and the best practice remains an unresolved issue.
Patients must take great care not to submerge the catheter and exit sites in water to minimize bacterial contamination. Occlusive, impermeable dressings should be used when bathing or showering. Aseptic techniques are essential when accessing and deaccessing TCVC catheter hubs. Personal protective equipment (gloves, gown, and eye protection) is used to minimize exposure to blood. Masks should be worn by staff and patients when manipulating the TCVC. Catheter hubs are disinfected with an appropriate antiseptic agent (e.g., 0.5% chlorhexidine with alcohol, 70% alcohol, or 10% povidone-iodine). When connecting (or disconnecting) TCVC hubs to ECP kit access and return lines do not allow the disinfected catheter to come into contact with nonsterile surfaces and minimize the time that the catheter hubs are uncapped and open. 21 At the completion of ECP the TCVC should be flushed and locked per institutional protocols. Locking solutions are used to prevent thrombotic obstruction of the catheter lumen and tip. Unfractionated heparin (100-5000 units/ mL), 4% citrate, and thrombolytic agents (e.g., tissue plasminogen activator [TPA]) are commonly used to lock catheters reserved for apheresis therapies. The volume of catheter locking solution is often found printed on the catheter clamp or may be obtained mathematically if the catheter diameter and length are known.
TRADITIONAL SUBCUTANEOUS PORT-CVC
Subcutaneous venous access devices are most commonly placed in patients with malignancies that require longterm chemotherapy. These implantable ports (port-CVC) may have single or double lumens and are constructed from titanium or plastic with polyurethane or silicon catheters. Ports and their attached catheters come in a variety of shapes and sizes thus port selection can be optimized to meet the treatment needs of the patient. The placement procedure of subcutaneous ports is similar to that used with TCVC except a port "pocket" is created at the skin insertion site to allow for complete, subcutaneous implantation of the device. Noncoring needles are passed through the skin and the self-sealing silicone septum to access the port reservoir for infusions and blood removal. There are at least two port-CVC on the market that are being used, "off-label," to provide reliable vascular access for single-needle ECP. 22, 23 The PowerPort with a 9.6 Fr polyurethane catheter (Bard Peripheral Vascular) and the Vortex Port with a 9.6 Fr silicone catheter (AngioDynamics). Both manufacturers offer dual-lumen ports that are used, "off-label," for RBC exchanges in patients with sickle cell disease. 24 In theory these port-CVC should be a viable option for double-needle ECP but their use in this setting has not been reported in peer reviewed literature. To achieve sufficient blood flow and maintain the integrity of the port septum, it is important that largegauge, typically 16-gauge, noncoring needles be used for access. These needles are designed with a metal stylet inside of a metal catheter that is inserted perpendicular to the port septum (Fig. 1) .
A meta-analysis of 14 prospective studies evaluating CRBSI risk associated with subcutaneous venous port-CVC showed a very low rate, 0.1 per 1000 IVD days, which is nearly 95% lower than the infection rates associated with TCVCs. 13 The subcutaneous port-CVC poises the lowest risk for CRBSIs, especially when the port-CVC is accessed relatively infrequently as is the case with ECP. This feature is particularly important for patients requiring ECP because many are already at increased risk of infection due to concomitant immunosuppression. Strict adherence to protocols designed to maintain aseptic conditions when accessing ports provide an additional safety measure. Flushing and locking protocols for subcutaneous ports are similar to those used for other CVC. 
SUBCUTANEOUS APHERESIS PORT-CVCs
Although traditional subcutaneous port-CVCs have been used for ECP, these ports are not designed or approved for apheresis therapies. Under the best conditions it is possible to achieve flow rates of 50-60 mL/min which is acceptable for ECP and RBC exchange, but usually not sufficient for other apheresis therapies. In April 2017 the FDA approved the first subcutaneous port-CVC specifically designed for apheresis, the PowerFlow implantable apheresis IV port (Bard Peripheral Vascular). 25 Its design is based on a predicate device, the Cathlink 20 titanium port. The Cathlink device was used "off label" in patients requiring chronic therapeutic plasma exchange until 2003 when the port was discontinued by the manufacturer.
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The PowerFlow device has a unique structure that differs considerably from traditional port-CVC. The port body is a titanium funnel coated in silicone for patient comfort. The funnel of the port guides a 16 or 14-gauge soft IV catheter to an angled needle stop. The catheter is advanced through a precut silicone valve that seals the IV catheter into the port. Unlike traditional port-CVCs that are accessed at 908, the apheresis port-CVC is accessed at 308 relative to the skin surface (Fig. 2 ). Blood flow rates at normal operating pressures (-100 mm Hg) range from 120 to 150 mL/min depending on the gauge of the IV catheter. 28 The fill volume of the apheresis IV port-CVC is approximately 1 mL. Heparin, citrate, and thrombolytics may be used to lock the port.
As of the publication date of this article, the apheresis port-CVC had only been on the market for a few months and there had not been time to accumulate data on infection risks. Presumably the port-CVC will have risks similar to other traditional subcutaneous port-CVC.
We began using the apheresis port at our institution in June 2017. At the time of manuscript submission we have performed more than 70 ECP procedures on five patients with either GVHD or CTCL. There have been no complications with the port-CVC and we consistently maintain flow rates of 30 to 50 mL/min on the ECP instrument without triggering pressure alarms. Although the inlet flow of the Therakos Cellex instrument may be adjusted up to 100 mL/min, we prefer the default maximum collect rate of 50 mL/min to minimize adverse reactions when citrate is used for anticoagulation during the procedure. Two of the five patients routinely develop symptoms of hypocalcemia (paresthesias and nausea) at rates more than 30 mL/min and their personal maximal inlet rates are set at 30 mL/min. We have achieved flow rates up to 100 mL/min during therapeutic plasma exchange procedures.
ARTERIOVENOUS FISTULAE AND GRAFTS
Arteriovenous fistulae and arteriovenous grafts are not typically considered for ECP therapy; however, if the patient has an existing ateriovenous fistula or ateriovenous graft it is possible to use the fistula for ECP. Only apheresis providers who are competent in fistula or graft access techniques should be allowed to cannulate the arteriovenous fistula.
COMPLICATIONS
Vascular access complications during the course of ECP therapy are not uncommon and vary depending on whether the access route is peripheral or central. Peripheral access complications include venous infiltration, pain at cannulation sites, thrombosis or sclerosis of veins, infection, and loss of future venous access due to scaring. 29 Complications that occur during or immediately following TCVC or port-CVC placement tend to be more serious and include pneumothorax, pneumopericardium, hemothorax, arterial puncture, cardiac arrhythmia, and hematomas. 18 The following sections describe some common complications with TCVC and port-CVC that occur later during the course of ECP treatment. Any changes or new symptoms at the TCVC or port-CVC site such as pain, swelling, erythema, or heat should prompt an appropriate evaluation.
Infection
The terms CRBSI and central line-associated blood stream infection (CLABSI) are often used interchangeably but there are different criteria that are used for classification. CRBSI is clinically defined as a bloodstream infection that is unequivocally associated with the central line. The patient must have clinical symptoms of infection and the same organism must be identified in the blood and through quantitative culture methods in a catheter segment. 21 CLABSI is defined by the CDC National Healthcare Safety Network as a bacteremia with at least one positive blood culture, clinical manifestations of infection, and no identifiable source of infection except the catheter. The temporal relationship is central line use within 48 hours of bloodstream infection. 21 The most common pathogens associated with CRBSI are Staphylococcus aureus, enterococci, and Candida spp. 30 Treatment of CRBSI or CLABSI is removal of the IVAD and appropriate antibiotics.
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Infections may also occur at the exit site or along the subcutaneous tunnel. These infections are characterized by erythema, swelling, pain, and often purulent drainage. If the infection is localized below the catheter cuff then oral antibiotic therapy is recommended. However, if the infection tracks above the cuff then the catheter must also be removed. 31 
Catheter dysfunction
Catheter dysfunction occurs when there is failure to achieve sufficient blood flow between the catheter and the apheresis instrument. Early dysfunction is usually mechanical in nature, for example, kinking of the catheter or incorrect catheter tip positioning. The use of fluoroscopy during catheter placement minimizes catheter dysfunction due to mechanical reasons. 18 Catheter-related sheaths (CRS) are a common cause of catheter dysfunction. More than 80% of long-term catheters will develop a sheath that may extend to the catheter tip creating a one-way valve that permits infusion but blocks withdrawal of blood. 32 The term "fibrin sheath" is a misnomer; the sheath is composed of a smooth muscle cell-collagen matrix that is covered by endothelial cells. In the first few days after catheter placement a thrombus develops between the injured vein wall and the catheter. Smooth muscle cells migrate into and across the thrombus creating bridges between the catheter and the vein wall. Over time the structure becomes endothelialized and will eventually form a permanent "scar" that persists after catheter removal. 33 Thrombolysis is usually the first step taken to restore blood flow when a CRS is obstructing the catheter tip. Recombinant TPA is the most common thrombolytic used in North America. TPA is placed into the catheter and allowed to dwell for at least 30 minutes before aspiration. This process may be repeated if adequate flow is not established on the first attempt. Alternatively, TPA can be reconstituted in 50 mL of normal saline and infused at a rate of 17 mL/hr. 18 If thrombolysis fails to restore blood flow the catheter should be replaced. At the time of the exchange angioplasty may be performed to disrupt the fragments of the CRS that remain attached to the vessel wall. 34 
Thrombus
The reported incidence of catheter-related thromboses (CRTs) in patients with long-term TCVC or port-CVC is highly variable,7% to 62%, and dependent on different patient populations and devices that are included in the studies. 35, 36 There are multiple factors that contribute to the development of CRT, which include underlying hypercoagulable states, large catheter lumen diameters, and tip positioning above the SVC/right atrial junction. 37 One of the most serious complications of CRT is a pulmonary embolism, which is estimated to occur in 10% to 15% of patients with CRT. 36 Patients with patent foramen ovale are at risk for ischemic stroke if emboli from the thrombus are shunted through the patent foramen ovale into left atrium and brain. 38 Other complications include swelling, pain, and loss of catheter function. Regular catheter flushes and instillation of anticoagulant locking solutions are traditionally used for prevention of CRT, but there is little evidence demonstrating the effectiveness of these practices. 39 The most commonly used anticoagulant locking solutions are heparin (100 to 5000 units/mL) and trisodium citrate (4%-47%). The anticoagulants appear to have similar effectiveness; however, when comparing heparin concentrations, higher doses seem to prevent thrombosis better than lower doses. 34 Functional lines that are required for therapy may remain in place as long as there is no evidence of infection, the tip is in the correct position and the patient is asymptomatic on systemic anticoagulation therapy. 40, 41 At least 3 months of systemic anticoagulation therapy is recommended for the treatment CRT.
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Central venous stenosis
Central venous stenosis is a complication of the trauma associated with TCVC or port-CVC placement. The inflamed endothelium induces intimal hyperplasia and fibrosis creating a stenosed scar in the vein. Patients may present with signs and symptoms of venous obstruction including swelling, erythema, and pain. 42 In extreme cases, SVC syndrome may develop when the SVC or bilateral brachiocephalic veins are obstructed. The syndrome is associated with bilateral edema of upper extremities, head, and neck. Patients with SVC syndrome require emergency intervention. Percutaneous transluminal angioplasty with or without stent placement is the preferred treatment for central venous stenosis. 42 The risk of venous stenosis can be reduced with advanced planning. Selecting IVAD with the smallest lumen size to support apheresis flow rates and rotating TCVC or port-CVC venous access sites will minimize venous trauma. 18 
QUALITY OF LIFE
An aspect of IVAD that is often overlooked and rarely evaluated is the effect of the device on the patient's quality of life. Studies show that patients who have port-CVCs report a higher quality of life when compared to patients with TCVCs. 43, 44 Port-CVCs are completely localized under the skin, which allows patients to bathe and swim without the need for occlusive dressings. Maintenance of port-CVCs with monthly line flushes is simpler than that for TCVCs, which require regular dressing changes and weekly line flushes. Patients with port-CVCs tend to feel less selfconscious because the port-CVC has minimal effects on cosmetic appearance. These factors combined with the reduced infectious complication rates indicate that subcutaneous port-CVCs should be utilized when possible for ECP and other apheresis therapies.
CONCLUSION
Vascular access for ECP procedures can be achieved by peripheral vein cannulation, TCVC, traditional subcutaneous port-CVC, and the newly approved apheresis port-CVC. CRS and CRT are complications that are not easily prevented but may be treated through angioplasty or systemic anticoagulation. Infection risks are decreased and quality-of-life indexes are increased when subcutaneous port-CVCs are used for long-term vascular access.
